Compare EOD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOD | LRMR |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.6M | 253.5M |
| IPO Year | N/A | 2014 |
| Metric | EOD | LRMR |
|---|---|---|
| Price | $5.73 | $3.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $14.20 |
| AVG Volume (30 Days) | 113.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-16-2026 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.51 | $1.92 |
| 52 Week High | $6.74 | $6.42 |
| Indicator | EOD | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 27.73 | 58.96 |
| Support Level | $5.51 | $2.89 |
| Resistance Level | $6.55 | $4.25 |
| Average True Range (ATR) | 0.13 | 0.30 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 10.14 | 66.40 |
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.